Tahlil

Respiratuar Sinsitial Virüs (RSV) Antikorları

Sanal Hastane||1 dk okuma
Respiratuar Sinsitial Virüs (RSV)  Antikorları

Klinik Kullanımı

RSV, insan solunum yolu enfeksiyonlarının önemli bir nedenidir. Çok sıklıkla ve ciddi olarak çocuklarda ortaya çıkar ve bronşiolitisinpnömoninin yaygın bir nedenidir. İleri yaştaki çocuklar ve yetişkinlerde daha orta derecede seyreder ve üst solunum yolunu kapsar.

Referans değerler

Ig M:<1:10

Ig G :<1:10

 

 

Kaynaklar ve Referanslar

  1. [1]Nam HH, Ison MG. Respiratory syncytial virus infection in adults.”. BMJ (Clinical research ed.). 2019. PMID: 31506273. PubMed →
  2. [2]Fly JH, Stultz JS, Eiland LS. Advancements in Respiratory Syncytial Virus (RSV) Prevention and Treatment in Pediatrics.”. The journal of pediatric pharmacology and therapeutics : JPPT. 2026. PMID: 42267066. PubMed →
  3. [3]McLellan JS, Chen M, Leung S, et al. Structure of RSV fusion glycoprotein trimer bound to a prefusion-specific neutralizing antibody.”. Science (New York, N.Y.). 2013. PMID: 23618766. PubMed →
  4. [4]Gonzalez C, Narla NP, Borch-Christensen B, Engel R, Kusma J. Bronchiolitis Post Introduction of RSV Immunoprophylaxis: Shifting Patterns in Pediatric Hospitalizations.”. Clinical pediatrics. 2026. PMID: 42210625. PubMed →
  5. [5]Marcandalli J, Fiala B, Ols S, et al. Induction of Potent Neutralizing Antibody Responses by a Designed Protein Nanoparticle Vaccine for Respiratory Syncytial Virus.”. Cell. 2019. PMID: 30849373. PubMed →
  6. [6]Mendes D, Lucas J, Quinones E, et al.. The Clinical and Symptomatic Burden Among Older Adults with Respiratory Syncytial Virus: A Real-World Survey in Five European Countries.”. Infectious diseases and therapy. 2026. PMID: 42287539. PubMed →
Paylaş: